Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations
Clinical and Translational Science · 2023
DOI: 10.1111/cts.13662 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2023. Verfasst von Erik Hahn und 4 weiteren Autor:innen. Beteiligte Einrichtung: Global Product Development, Pfizer Inc., Boulder, Colorado, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Colorectal Neoplasms, Melanoma. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Encorafenib is a potent and selective ATP competitive inhibitor of BRAF V600–mutant kinase approved for patients with BRAF‐mutant melanoma and colorectal cancer. Encorafenib is mainly metabolized by cytochrome P450 (CYP) 3A4 in vitro and may be susceptible to drug–drug interactions when co‐administered with CYP3A inhibitors or inducers. The primary objective was to assess the impact of the strong CYP3A inhibitor posaconazole (part 1) and the moderate CYP3A and P‐gp inhibitor diltiazem (part 2) on encorafenib pharmacokinetics in healthy volunteers following a single 50‐mg dose. A total of 32 participants were enrolled (16 each in parts 1 and 2). The area under the curve extrapolated to infinity (AUC inf ) and maximum plasma concentration ( C max ) geometric mean for encorafenib increased by 183% and 68.4%, respectively, when co‐administered with posaconazole. Apparent encorafenib clearance decreased from 26.0 to 9.2 L/h when coadministered with posaconazole, and plasma terminal half‐life ( t ½ ) of encorafenib increased from 4.3 to 7.3 h. The AUC inf and C max geometric mean for encorafenib increased by 83.0% and 44.7%, respectively, when co‐administered with diltiazem. Similarly, the apparent encorafenib clearance decreased from 29.0 to 16.0 L/h when co‐administered with diltiazem, and plasma t ½ of encorafenib increased from 6.6 to 7.9 h. There were no deaths, serious adverse events (AEs), or patient discontinuations due to AEs in parts 1 or 2. The most frequently reported treatment‐related AEs were erythema ( n = 14; 88%) and headache ( n = 11; 69%) in part 1 and headache ( n = 7; 44%) in part 2. The results of this study indicate that co‐administration of encorafenib with strong or moderate CYP3A4 inhibitors should be avoided.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Global Product Development, Pfizer Inc., Boulder, Colorado, USA.
- Early Clinical Development, Pfizer Inc., Boulder, Colorado, USA.
- Global Product Development, Pfizer Inc., La Jolla, California, USA.
ORCID-Profile: Erik Hahn, Renae Chavira, Lance Wollenberg, Micaela B Reddy
Zitieren
APA
Hahn, E., Chavira, R., Wollenberg, L., Tan, W., & Reddy, M. B. (2023). Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations. Clinical and Translational Science. https://doi.org/10.1111/cts.13662
Vancouver
Hahn E, Chavira R, Wollenberg L, Tan W, Reddy MB. Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations. Clinical and Translational Science. 2023. doi:10.1111/cts.13662
BibTeX
@article{Hahn2023,
author = {Hahn, Erik and Chavira, Renae and Wollenberg, Lance and Tan, Weiwei and Reddy, Micaela B},
title = {Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations},
journal = {Clinical and Translational Science},
year = {2023},
doi = {10.1111/cts.13662}
}
EUVIMED